TrialBlood2024

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Othman Al-Sawaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.